Ertugliflozin and Metformin

Therapeutic Group

Blood Glucose Lowering Drugs, Excluding Insulin

Indication Dosage

Ertugliflozin and Metformin is a combination medication designed to treat type 2 diabetes mellitus. Ertugliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that works by promoting the excretion of glucose in the urine, thereby lowering blood sugar levels. Metformin, on the other hand, is a biguanide that improves insulin sensitivity and reduces glucose production in the liver. This combination offers a dual mechanism of action to help control hyperglycemia in patients with type 2 diabetes. Ertugliflozin and Metformin are typically prescribed as an adjunct to diet and exercise when monotherapy with metformin or ertugliflozin alone is insufficient. 

Dosage:

2.5mg Ertugliflozin/ 500mg Metformin twice daily; increase the dose as required. Max: 7.5, 5mg Ertugliflozin/ 1000mg Metformin.

Content

  • Tab 2.5mg/ 500mg: Ertugliflozin and Metformin
  • Tab 2.5mg/ 1000mg: Ertugliflozin and Metformin
  • Tab 7.5mg/ 500mg: Ertugliflozin and Metformin
  • Tab 7.5mg/ 1000mg: Ertugliflozin and Metformin

Pregnancy

Contraindicated in Pregnancy

Stability

  • Sodium-glucose cotransporter-2 (SGLT2) inhibitor
  • Biguanide

Contra Indications

  • Type 1 Diabetes Mellitus, Severe Renal Impairment, end-stage Renal Disease, or Dialysis, Pancreatitis, Ketoacidosis, Hepatic Impairment.

Precautions

  • Type 1 Diabetes Mellitus, Severe Renal Impairment, end-stage Renal Disease, or Dialysis, Pancreatitis, Ketoacidosis, Hepatic Impairment.

Lactation

  • Contraindicated or Not Recommended

Side Effects

  • Headache
  • Abdominal Discomfort
  • Diarrhoea
  • Flatulence
  • Nausea
  • Vomiting
  • Genital Mycotic Infection

Available Brands